ATE254918T1 - Orale flüssige lösung enthaltend das antidepressivum mirtazapine - Google Patents

Orale flüssige lösung enthaltend das antidepressivum mirtazapine

Info

Publication number: ATE254918T1
Authority: AT; Austria
Prior art keywords: solution containing; oral liquid; liquid solution; mirtazapine; antidepressant mirtazapine
Prior art date: 1998-04-02

Application number

AT99917956T

Other languages

English (en)

Inventor

Arnold Titus Philip Skrabanja

Roger Edward Tully

Original Assignee

Akzo Nobel Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-04-02

Filing date

1999-03-29

Publication date

2003-12-15

1999-03-29 Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv

2003-12-15 Application granted granted Critical

2003-12-15 Publication of ATE254918T1 publication Critical patent/ATE254918T1/de

Links

229960001785 mirtazapine Drugs 0.000 title abstract 3
RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 title abstract 3
230000001430 anti-depressive effect Effects 0.000 title abstract 2
239000000935 antidepressant agent Substances 0.000 title abstract 2
229940005513 antidepressants Drugs 0.000 title 1
239000006193 liquid solution Substances 0.000 title 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 abstract 1
230000003444 anaesthetic effect Effects 0.000 abstract 1
239000007864 aqueous solution Substances 0.000 abstract 1
239000007900 aqueous suspension Substances 0.000 abstract 1
238000009472 formulation Methods 0.000 abstract 1
239000003589 local anesthetic agent Substances 0.000 abstract 1
229930182817 methionine Natural products 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Pain & Pain Management (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Cosmetics (AREA)

AT99917956T 1998-04-02 1999-03-29 Orale flüssige lösung enthaltend das antidepressivum mirtazapine ATE254918T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP98201037		1998-04-02
PCT/EP1999/002277 WO1999051237A1 (en)	1998-04-02	1999-03-29	Oral liquid antidepressant solution

Publications (1)

Publication Number	Publication Date
ATE254918T1 true ATE254918T1 (de)	2003-12-15

Family

ID=8233550

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT99917956T ATE254918T1 (de)	1998-04-02	1999-03-29	Orale flüssige lösung enthaltend das antidepressivum mirtazapine

Country Status (11)

Country	Link
US (2)	US6040301A (de)
EP (1)	EP1067934B1 (de)
AT (1)	ATE254918T1 (de)
AU (1)	AU747975B2 (de)
BR (1)	BR9909357A (de)
CA (1)	CA2326356C (de)
DE (1)	DE69913116T2 (de)
DK (1)	DK1067934T3 (de)
ES (1)	ES2212550T3 (de)
PT (1)	PT1067934E (de)
WO (1)	WO1999051237A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6495534B2 (en) *	2000-05-15	2002-12-17	Pharmacia & Upjohn Spa	Stabilized aqueous suspensions for parenteral use
US20030105082A1 (en) *	2001-12-03	2003-06-05	Murphy Greer Marechal	Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
DE60224078T2 (de) *	2001-02-12	2008-12-04	N.V. Organon	Verwendung von Mirtazapin zur Verbesserung der Behandlung von Menschen mit starken Depressionen, welche Träger des Gens für Apolipoprotein E4 sind.
US6399310B1 (en)	2001-02-12	2002-06-04	Akzo Nobel N.V.	Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
US20040156894A1 (en) *	2003-02-07	2004-08-12	Grother Leon Paul	Use of edible acids in fast-dispersing pharmaceutical solid dosage forms
US7838029B1 (en) *	2003-07-31	2010-11-23	Watson Laboratories, Inc.	Mirtazapine solid dosage forms
TW200538100A (en) *	2004-04-21	2005-12-01	Akzo Nobel Nv	Mirtazapine salts
US20060039866A1 (en) *	2004-08-20	2006-02-23	Cypress Bioscience, Inc.	Method for treating sleep-related breathing disorders
US20060058390A1 (en) *	2004-09-14	2006-03-16	Molecular Therapeutics, Inc.	D-methionine formulation with improved biopharmaceutical properties
JP2008519055A (ja) *	2004-11-08	2008-06-05	シャイアエルエルシー	ミルタザピンと興奮剤複合物の併用投与の相乗効果
TW200631584A (en) *	2004-11-15	2006-09-16	Akzo Nobel Nv	A medicament related to mirtazapine for the treatment of hot flush
EP1827450A4 (de) *	2004-11-17	2009-04-22	Cypress Bioscience Inc	Verfahren zur verringerung der nebenwirkungen einer behandlung mit mirtazapin
EP2167096A4 (de) *	2007-06-13	2010-07-14	Cypress Bioscience Inc	Verbesserung der verträglichkeit von mirtazapin und eines zweiten wirkstoffes durch ihre kombinierte verwendung
WO2011140358A2 (en)	2010-05-05	2011-11-10	Ener-G-Rotors, Inc.	Fluid energy transfer device
US8714951B2 (en) *	2011-08-05	2014-05-06	Ener-G-Rotors, Inc.	Fluid energy transfer device
WO2016138357A1 (en)	2015-02-27	2016-09-01	Kindred Biosciences, Inc.	Stimulation of appetite, management of weight loss, and treatment of anorexia in dogs and cats

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL189199C (nl) *	1975-04-05	1993-02-01	Akzo Nv	Werkwijze ter bereiding van farmaceutische preparaten met werking op het centraal zenuwstelsel op basis van benz(aryl)azepinederivaten, de verkregen gevormde farmaceutische preparaten, alsmede werkwijze ter bereiding van de toe te passen benz(aryl)azepinederivaten.
US5208261A (en) *	1989-12-06	1993-05-04	Akzo N.V.	Stabilized solutions of psychotropic agents
DK0431663T3 (da) *	1989-12-06	1994-03-07	Akzo Nobel Nv	Stabiliserende opløsninger af psykotrope midler
IE63986B1 (en) *	1989-12-30	1995-06-28	Akzo Nv	Pharmaceutical preparation for oral administration in fluid form
US5238699A (en) *	1991-11-27	1993-08-24	Kraft General Foods, Inc.	Ready-to-eat, low/no-fat puddings and process

1999
- 1999-03-29 DE DE69913116T patent/DE69913116T2/de not_active Expired - Lifetime
- 1999-03-29 DK DK99917956T patent/DK1067934T3/da active
- 1999-03-29 CA CA002326356A patent/CA2326356C/en not_active Expired - Fee Related
- 1999-03-29 AT AT99917956T patent/ATE254918T1/de active
- 1999-03-29 WO PCT/EP1999/002277 patent/WO1999051237A1/en not_active Ceased
- 1999-03-29 AU AU36048/99A patent/AU747975B2/en not_active Ceased
- 1999-03-29 EP EP99917956A patent/EP1067934B1/de not_active Expired - Lifetime
- 1999-03-29 PT PT99917956T patent/PT1067934E/pt unknown
- 1999-03-29 BR BR9909357-0A patent/BR9909357A/pt not_active Application Discontinuation
- 1999-03-29 ES ES99917956T patent/ES2212550T3/es not_active Expired - Lifetime
- 1999-04-01 US US09/283,945 patent/US6040301A/en not_active Expired - Fee Related
- 1999-07-22 US US09/358,772 patent/US6114324A/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
ES2212550T3 (es)	2004-07-16
DE69913116D1 (de)	2004-01-08
HK1032012A1 (en)	2001-07-06
BR9909357A (pt)	2000-12-12
EP1067934B1 (de)	2003-11-26
AU3604899A (en)	1999-10-25
CA2326356A1 (en)	1999-10-14
US6040301A (en)	2000-03-21
US6114324A (en)	2000-09-05
CA2326356C (en)	2008-06-03
DE69913116T2 (de)	2004-06-03
EP1067934A1 (de)	2001-01-17
WO1999051237A1 (en)	1999-10-14
DK1067934T3 (da)	2004-03-29
PT1067934E (pt)	2004-03-31
AU747975B2 (en)	2002-05-30

Legal Events

Date

Code

Title

Description

2004-10-15

UEP

Publication of translation of european patent specification

Ref document number: 1067934

Country of ref document: EP

Publication	Publication Date	Title
ATE254918T1 (de)	2003-12-15	Orale flüssige lösung enthaltend das antidepressivum mirtazapine
BR9917007A (pt)	2001-10-30	Moduladores de ccr5
BR9906758A (pt)	2002-01-15	Método e composição para transferir zinco para a membrana nasal
PT94504A (pt)	1991-02-08	Processo para a preparacao de composicoes farmaceuticas aquosas em suspensao para ingredientes activos substancialmente insoluveis em agua
NO962539D0 (no)	1996-06-14	5-(2-imidazolinylamino)benzimidazol-derivater, deres fremstilling og deres anvendelse som -2-adreniceptor-agonister
BR0213358A (pt)	2004-10-26	Uso de flibanserina
BRPI0111639B8 (pt)	2021-05-25	uso de uma molécula de ácido oligodeoxinucléico imunoestimulatório e composição farmacêutica.
DK0894084T3 (da)	2002-10-14	Kanelsyrederivater og deres anvendelse som integrinantagonister
TR200200579T2 (tr)	2002-12-23	Amino-tirazolpiridin türevleri.
NO970051L (no)	1997-01-07	Vandige risperidon formuleringer
NO20022201L (no)	2002-05-08	Lösninger inneholdende Epinastin
KR950031060A (ko)	1995-12-18	골다공증 치료용 약제학적 조성물
DE69818026D1 (de)	2003-10-16	Wässrige suspension zur nasalen verabreichung von loteprednol
BR0105563A (pt)	2002-04-02	Derivados e análogos de galantamina
BR9916575A (pt)	2001-09-18	Composição farmacêutica de liberação controlada com mesilato de tilidina como substância-ativa
BR9805265A (pt)	2000-04-11	Sìlicas precipitadas que contêm uma substância ativa.
FI962492A0 (fi)	1996-06-14	Alpha-2-adrenoseptoriagonisteina käyttökelpoisia 7-(2-imidatsolinyyliamino)kinoliiniyhdisteitä
NO20014241D0 (no)	2001-08-31	C16-umettede FP-selektive prostaglandinanaloger
ATE201680T1 (de)	2001-06-15	2,3,4,5-tetrahydro-1h-3-benzazepin säure- additions-salze
PT1204658E (pt)	2003-08-29	Agonistas benzofurilpiperazina de serotonina
KR900018091A (ko)	1990-12-20	진경제
GR1001511B (el)	1994-02-28	Στεροειδείς συν?έσεις.
PT1257552E (pt)	2005-01-31	Derivados de xantina, intermediarios e aplicacao ao tratamento de osteoporose
HRP20020332B1 (hr)	2011-02-28	Oralne otopine koje sadrže galantamin i sladilo
DK0725776T3 (da)	1997-09-01	3-Aryl-4-alkyl- og 4,5-dialkyl-4H-1,2,4-triazoler anvendelige som hukommelsesforbedrende midler